Tests cyproheptadine for leaky heart valve caused by heart attack damage
Tests cyproheptadine against placebo in adults with ischemic mitral regurgitation.
Plain-language title generated from the registry record
Registry title: Serotonin Receptor Blockers in Ischemic Mitral Regurgitation
Key facts
- Where
- Québec, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-80 after a first heart attack (STEMI) with a blocked heart artery and weakened heart pumping. It tests cyproheptadine against placebo for mitral regurgitation.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- First STEMI with documented coronary obstruction. Left ventricle ejection fraction (LVEF) below 50% with mitral tenting area of 4 cm2 or more, OR LVEF 40% or less with a wall motion problem in the inferior/posterior wall, OR LVEF 30% or less with a wall motion problem in any area.
- Earlier treatment
- People on ongoing treatment with a selective serotonin reuptake inhibitor (SSRI), or chronic use of sedative medication, cannot join. Prior mitral valve procedure or surgery is also not allowed.
Main reasons for not taking part
- Unstable blood circulation, cardiogenic shock or papillary muscle rupture
- Prior mitral valve procedure or surgery, or primary mitral valve disease
- Permanent atrial fibrillation
- Ongoing or planned pregnancy
- Chronic kidney failure with eGFR below 30 mL/min
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05469165, who can take part
Where in Canada
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université LavalQuébec, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Laval University
- Trial code
- NCT05469165
- Record updated
- 15 November 2023
- Original description
This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.Read full original descriptionShow less
Blocking the Effects of Serotonin to Prevent Ischemic Mitral Regurgitation: a Randomized Trial (CYPRO-MR)
This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.
Inclusion: Patients 18-80 years old with a 1st episode of STEMI with documented coronary obstruction; Left ventricle ejection fraction (LVEF)<50% and mitral tenting area ≥ 4 cm2, OR LVEF ≤ 40% and inferior/posterior wall motion anomaly, OR LVEF≤30% and wall motion in any territory.
Exclusion: Prior mitral valve procedure/surgery; Ongoing treatment with selective serotonin reuptake inhibitor (SSRI); Chronic use of sedative medication; Symptom or prior episode of urinary obstruction or glaucoma (relative contraindications for cyproheptadine); Primary mitral disease (endocarditis, rheumatic, degenerative or congenital); More than mild valvular disease (other than mitral) at baseline; Planned cardiac surgery (CABG or valve intervention) within 3 months; Neurocognitive disorder; Chronic renal failure with Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min; Inability to provide informed consent; Hemodynamic instability / cardiogenic shock / papillary muscle rupture; Permanent atrial fibrillation (limiting imaging and MR quantification); Contraindications for MRI; Ongoing or planned pregnancy.